The Case for Proton Beam Therapy

This patient with Barcelona Clinic Liver Cancer stage A hepatocellular carcinoma (HCC) in the setting of nonalcoholic fatty liver disease–related Child-Pugh A5 cirrhosis should be strongly considered for definitive hypofractionated proton beam therapy (PBT) (1). The physical characteristics of protons make them particularly attractive and well suited for treatment of patients with HCC. PBT deposits the majority of dose at the Bragg peak with little to no exit dose, which is beneficial for patients with HCC because of the radiosensitivity of the normal liver, especially to low doses.

https://ift.tt/2DFWabI